• Abiraterone Acetate in 3D Prostate Cancer Models

  2026-09-16

  Abiraterone acetate is more than a CYP17 inhibitor: it is a mechanistic probe for testing how androgen biosynthesis, prodrug activation, and three-dimensional tumor architecture shape treatment response. By pairing the compound with patient-derived prostate spheroids, translational researchers can distinguish target engagement from simple viability loss and better interpret why organ-confined models may respond differently from castration-resistant prostate cancer systems.

• Firefly Luciferase mRNA: R1013 Guide

  2026-09-15

  Firefly Luciferase mRNA R1013 is a 5-moUTP modified mRNA for transient luciferase expression and bioluminescent reporter gene assays. Its Cap1 structure, modified uridines, and approximately 100-nucleotide poly(A) tail support translation-oriented workflows, but delivery and substrate conditions remain experimental variables.

• Dissecting Drug Response in Cancer In Vitro

  2026-09-15

  Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating proliferative arrest from cell death and considering their timing, the work provides a more precise framework for interpreting in vitro drug responses and designing cancer research workflows.

• Foretinib (GSK1363089): Mechanism & Evidence

  2026-09-14

  Foretinib, also called GSK1363089, is an ATP-competitive multikinase inhibitor that combines potent Met, VEGFR, Tie-2, and RON inhibition with reported activity in tumor growth, motility, invasion, and metastasis models. Its research value is strongest when kinase potency, cell-state responses, cell motility, and fractional cell death are measured as separate endpoints.

• The Translational Logic of ARCA EGFP mRNA

  2026-09-14

  A thought-leadership analysis of how cap orientation, 5-moUTP chemistry, polyadenylation, handling discipline, and storage strategy shape the value of ARCA EGFP mRNA (5-moUTP) as a translational control for mRNA delivery studies.

• TRPV1 and TRPA1 Drive TSLP in Nasal Epithelium

  2026-09-13

  The reference study identifies a calcium-dependent TRPV1/TRPA1–NFAT pathway that promotes TSLP production in nasal epithelial cells. Its experimental design connects epithelial ion-channel activation with upper-airway inflammatory signaling while distinguishing the stronger causal evidence for TSLP from more preliminary findings involving IL-25 and IL-33.

• Cy3-UTP Workflow for RNA Trafficking Studies

  2026-09-12

  Cy3-UTP enables bright, traceable RNA for imaging, binding assays, and delivery research. This practical guide links controlled in vitro transcription RNA labeling with LNP trafficking measurements while clarifying what fluorescent RNA can—and cannot—report.

• Rotigotine Analytical Methods: Impurities and Stability

  2026-09-11

  The reference review integrates pharmacopoeial and literature methods for measuring Rotigotine in raw material and transdermal patches, with particular attention to related impurities, oxidative degradation, and enantiomeric purity. Its practical contribution is a quality-control framework for developing stability-indicating assays while highlighting the limited pharmacokinetic and toxicological characterization of Rotigotine impurities.

• Fulvestrant: An ERα Probe for Cancer and Immunity

  2026-09-11

  Fulvestrant (ICI 182,780) is more than an estrogen receptor degrader for advanced breast cancer. This article explains how to use its receptor-level perturbation logic to distinguish ERα, GPR30, and endoplasmic reticulum stress effects in translational assays.

• Nebivolol Hydrochloride: β1 Research Guide

  2026-09-10

  Nebivolol hydrochloride is a potent β1-adrenoceptor antagonist for receptor-signaling and cardiovascular pharmacology research. Product data report an IC50 of 0.8 nM, while a 2025 yeast study found no evidence that nebivolol inhibits TOR under its tested conditions.

• GSK126 and the Translational Logic of EZH2 Biology

  2026-09-10

  GSK126 offers translational researchers a precise way to interrogate EZH2-driven chromatin repression, connecting tumor biology with immune-regulatory models. This thought-leadership perspective links PRC2 mechanism, cancer epigenetics research, experimental design, and the broader relevance of H3K27me3-dependent gene control.

• TAK1–YAP Control of Gastric Cancer Stem Cells

  2026-09-09

  The reference study identifies TGFβ-activated kinase 1 (TAK1) as an upstream regulator of YAP stability in gastric cancer stem cells. Its findings connect IL-6–induced TAK1 expression with YAP preservation, SOX2/SOX9 transcription, stem-cell self-renewal, and gastric tumorigenesis, providing a mechanistic framework for cancer research and future treatment-response studies.

• Gly-Gly-Phe-Gly (GGFG) Linker Workflow

  2026-09-09

  Gly-Gly-Phe-Gly (GGFG) provides a compact, sequence-defined spacer for drug conjugation research, peptide engineering, and biomaterial construction. This workflow connects practical handling and coupling controls with mechanistic assay design inspired by multiple myeloma research, while clearly separating linker performance from disease biology.

• Rotigotine Analytical Methods and Impurity Control

  2026-09-08

  This review consolidates chromatographic and related analytical methods for Rotigotine raw material, transdermal formulations, impurities, degradation products, and enantiomeric purity. Its main practical contribution is to connect pharmacopoeial procedures with literature methods, while identifying unresolved stability, pharmacokinetic, and toxicological questions that remain important for Parkinson’s disease research.

• Nebivolol hydrochloride in β1 Signaling Assays

  2026-09-08

  Nebivolol hydrochloride provides a precise β1-adrenoceptor antagonist tool for dissecting cardiac signaling while serving as a useful negative comparator in mTOR/TOR discovery workflows. This article combines formulation guidance, receptor-assay design, yeast counter-screening, and troubleshooting for more interpretable cardiovascular pharmacology research.

7744 records 1/517 page Next 12345 下5页 Last page